Perioperative Low-dose Dexmedetomidine Decreases Incidence of Delirium in Liver Transplant Patients

Trial Profile

Perioperative Low-dose Dexmedetomidine Decreases Incidence of Delirium in Liver Transplant Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Delirium; Sedation
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Nov 2017 Planned End Date changed from 1 Jul 2017 to 1 Feb 2018.
    • 26 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 03 Nov 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Nov 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top